Kazumasa Hirata’s resume includes more than 15 years of pharmaceutical industry experience specializing in dermatological drug development. Dr. Hirata began his career as a pharmacokinetics researcher, responsible for conducting ADME [Absorption, Distribution, Metabolism and Excretion] studies for drug candidate applications to PMDA [Pharmaceuticals and Medical Devices Agency], the chief regulatory authority in Japan. He has served as Project Manager in the United Kingdom, overseeing and managing drug development projects in the therapeutic categories of pruritus associated with atopic dermatitis, psoriasis, genital herpes and herpes zoster. Dr. Hirata joined Cutanea Life Sciences in February, 2016, as Vice President of Corporate development. He is a member of the CLS Board of Directors and as well as the President/CEO Leadership Team. As such, he is the primary liaison between CLS and its parent company, Maruho Co., Ltd. in Japan, responsible for facilitating operational communications between the two organizations. Dr. Hirata also serves as a member of the Portfolio Enrichment Committee, whose purpose is to identify potential new business opportunities which can advance the future development and growth of the company’s product portfolio.
Dr. Hirata obtained his Ph.D. from The School of Pharmacy, University of London (presently UCL School of Pharmacy). The title of his thesis was “Topical Formulation Strategies for a Model Acidic and a Model Basic Drug.”